Table of Contents
1
UI - 11554237
AU - Yetgin S; Olcay L; Yenicesu I; Oner AF; Caglar M
TI -
Relapse in hairy cell leukemia due to isolated nodular skin
infiltration.
SO - Pediatr Hematol Oncol 2001 Sep;18(6):415-7
Leukemic skin infiltration is quite uncommon in certain types of
leukemia. Here, a child with hairy cell leukemia who developed isolated
skin infiltration during remission is reported. The failure to diagnose
the leukemic infiltration until the nodule reached a diameter of 2 cm is
emphasized.
2
UI - 11837463
AU - Srivastava A; Mathews V
TI -
Hairy cell leukaemia--therapeutic options.
SO - J Assoc Physicians India 2001 Aug;49():783-4
3
UI - 11837464
AU - Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
TI -
2-CdA in the treatment of hairy cell leukaemia.
SO - J Assoc Physicians India 2001 Aug;49():785-7
AD - Department of Medical Oncology, Tata Memorial Hospital, Mumbai.
INTRODUCTION: Hairy cell leukaemia (HCL) is a rare lymphoproliferative
disorder. Treatment options available are splenectomy, interferon, DCF
and 2-CdA. 2-CdA is considered to have curative potential as proved by
the other studies. METHODS: We gave 2-CdA in a dose of 0.09/kg/day as a
continuous infusion in sixteen patients of hairy cell leukaemia.
RESULTS: Three patients developed neutropenia post transfusion. At the
end of three months all patients were in remission. Two patients
relapsed at the median follow-up of 15 months. CONCLUSION: 2-CdA in HCL
can achieve complete remission, prolonged survival and care as well.
4
UI - 11860448
AU - Nishii K; Katayama N; Maeda H; Usui E; Takemitu T; Lorenzo V F; Nakase
TI -
K; Shiku H
Successful treatment with low-dose splenic irradiation for massive
splenomegaly in an elderly patient with hairy-cell leukemia.
SO - Eur J Haematol 2001 Oct;67(4):255-7
AD - Second Department of Internal Medicine, Mie University School of
Medicine, Tsu, Mie, Japan. kaz@clin.medic.mie-u.ac.jp
The therapeutic approach to hairy-cell leukemia (HCL) is in some
instances still debated. Although management with alpha-interferon and
purine analogues is well established, there is an alternative role for
therapeutic splenectomy in patients with massive splenomegaly who have
failed to respond to systemic therapy. Most patients with HCL will not
be suitable for treatment with splenectomy as their ages at diagnosis
are high. Here, we report an elderly Japanese HCL patient whose
refractory massive splenomegaly responded well to low-dose splenic
irradiation.
5
UI - 11755467
AU - Khalaf W; Maina C; Byers J; Harvey W
TI -
Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis
factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell
leukemic cell line. A potential cytokine and oncogene relationship
regulating apoptosis is suggested.
SO - Leuk Res 2002 Feb;26(2):169-77
AD - Department of Microbiology and Immunology, Indiana University School of
Medicine, Indianapolis, IN 46222, USA.
The in vitro effects of interferon-alpha (IFN) on levels of secreted
interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF alpha), and
nuclear matrix proteins (NMP) were examined in ESKOL, a B-lymphoblastoid
cell line resembling hairy cell leukemia (HCL). IFN enhances
differentiation in ESKOL, decreases TNF alpha levels, decreases
apoptosis, increases IL-6 levels, and down regulates the expression of
several oncogenes. Vesnarinone (Ves), a TNF alpha repressor, lowers
TNF-alpha and decreases apoptosis in the same cell line. ESKOL exhibits
enhanced apoptosis and reduced B-cell lymphomas (Bcl-2) levels over
WIL-2. IL-6 and TNFalpha have been shown to decrease and increase
apoptosis in B-cells respectively; however, treatment of ESKOL with
these cytokines had no significant effect on apoptosis. We suggest that
IFN decreases apoptosis by mechanisms involving enhanced IL-6 and Bcl-2
levels, decreased TNF alpha and the down regulation of apoptotic
oncogenes, including c-myc.
6
UI - 11821443
AU - Federico M; Zinzani PL; Frassoldati A; Vinceti M; Mode A; Annino L;
TI -
Chisesi T; Pagnucco G; Invernizzi R; Spriano M; Resegotti L; Bendandi M;
Damasio EE; Italian Cooperative Group for the Study of Hairy Cell
Leukemia
Risk of second cancer in patients with hairy cell leukemia: long-term
follow-up.
SO - J Clin Oncol 2002 Feb 1;20(3):638-46
AD - Oncologia Medica and Dipartimento di Scienze Igienistiche, Universita di
Modena e Reggio Emilia, Modena, Italy. federico@unimo.it
PURPOSE: The purpose of the present study was to assess the risk of
second cancers in patients with hairy cell leukemia (HCL). PATIENTS AND
METHODS: We investigated the incidence of additional cancers in those
patients registered in the nationwide registry of the Italian
Cooperative Group for the Study of HCL, asking the cooperating centers
for additional information on initial and subsequent therapies and on
time and type of second malignancies, if they developed. Here we report
the final results of this survey, consisting of 54 cases of second
malignancies (excluding nine cases of epithelial skin cancer) which
developed in 54 patients of 1,022 with adequate follow-up. RESULTS: The
cumulative risk of development of a second cancer was 5%, 10%, and 14%
at 5, 10, and 15 years, respectively. The incidence of second
malignancies was not significantly higher than the expected rate
(standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI],
0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin's lymphoma in
the entire cohort was 5.3 (95% CI, 1.9 to 11.5). Second malignancies
occurred in eight (4.7%) of 386 patients who never received interferon
(IFN), nine (5.9%) of 495 patients treated with IFN at the time of
diagnosis, and seven (6.9%) of 102 patients who received IFN as
second-line therapy. These differences were not statistically
significant. Analysis of the separate calendar periods did not reveal
any particular trends with respect to variations in SIR. CONCLUSION: The
present study does not support the suspicion that patients with HCL are
at increased risk of additional second malignancies, although the
incidence of lymphoid neoplasms was significantly higher than expected.
In addition, our data indicate that IFN therapy did not exert an
oncogenic effect in such patients.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home